Evaluation of the JAK2 V617F gene mutation in myeloproliferative neoplasms cases: a one-center study from Eastern Anatolia

Gülbay G., YEŞİLADA E., ERKURT M. A., BAG H. G., KUKU İ., KAYA E.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.44, no.4, pp.492-498, 2019 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1515/tjb-2018-0054
  • Journal Name: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.492-498
  • Keywords: Janus Kinase2, JAK-STAT pathway, Myeloproliferative disorders, JAK2 V617F mutation, Real-time poly-merase chain reaction, TYROSINE KINASE JAK2, POLYCYTHEMIA-VERA, ESSENTIAL THROMBOCYTHEMIA, EXON-12 MUTATIONS, DISORDERS, FREQUENCY, ASSOCIATIONS, JAK2(V617F), PREVALENCE, PHENOTYPE
  • Inonu University Affiliated: Yes

Abstract

Objective: Detection of JAK2 V617F in myeloproliferative neoplasms (MPNs) is very important in both diagnosis and disease progression. In our study, we investigated the frequency of JAK2 V617F mutation in patients with myeloproliferative disorders.